Amylin second-quarter total revenues up at $118.1 million

By Lisa Kerner

Charlotte, N.C., July 24 - Amylin Pharmaceuticals, Inc. reported total revenues of $118.1 million, including net product sales of $108.8 million, for the second quarter ended June 30, up from the prior-year period total revenues of $46.7 million, including net product sales of $8.6 million.

Net loss was $46.4 million, or $0.38 per share, for the quarter, compared to $26.6 million, or $0.26 per share, for the same period in 2005.

Total revenues for the six months ended June 30 were $200.5 million, including net product sales of $184.7 million, compared to net product sales of $8.7 million for the same period in 2005.

For the six months ended June 30, net loss was $114.3 million, or $0.97 per share, an increase from the $70.2 million, or $0.68 per share, reported for the same period in 2005.

At June 30, the company held cash, cash equivalents and short-term investments of about $856 million.

Highlights for the quarter include a completed public offering of common stock generating net proceeds of $508 million and submission of a supplemental New Drug Application for a disposable pen delivery system for Symlin.

Amylin is a San Diego-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.